InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,505.00
(
-0.71%
)
US TECH 100
19,000.00
(
-0.94%
)
Dow Jones
40,287.53
(
-0.93%
)
Brent Oil
81.88
(
0.00%
)
Bitcoin
66,644.57
(
-0.11%
)
Post# of 252642
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120081
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: turtlepower post# 97037

Thursday, 06/10/2010 6:11:59 PM

Thursday, June 10, 2010 6:11:59 PM

Post# of 252642
Re: IDX320 dosing regimen

Following up on mcbio’s reply in #msg-51128566, I noticed in the slide set of today’s Jefferies webcast that IDX320 has a half-life in humans of 26 hours, which is about 3x the half-life that was seen in monkeys. Thus, qD doing of IDX320 is assured except in genotype-3a, where IDX320 has weaker antiviral activity than in other genotypes.

The planned BID dosing of IDX320 in gentotype-3a is not mandated by the PK; rather, it is simply a way for IDIX to double the cumulative daily dose without having to develop a separate tablet just for this genotype.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up